Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
Alcohol and other drugs are a major issue in Australia and Burnet has an established reputation in working to alleviate harms associated with their use.
BDI is a commitment by Burnet Institute to develop the systems, resources, and processes to support diagnostics product development and enhance translation of its point-of-care diagnostics research into practical health solutions.
Understanding the role of key signalling molecules that are critical for the normal development and function of T and B lymphocytes.
Adolescence as a key developmental stage within the life-course, where investments bring a triple dividend of benefits – now, into future adult life, and for the next generation of children.
Translating research into sustainable health solutions for vulnerable communities through health system strengthening, improved health service delivery and empowering communities.
Improving health outcomes for at-risk mothers and newborn babies.
Conducts innovative research aimed at understanding the transmission and prevention of HIV.
Identifying risk factors for HIV acquisition in young South African women and developing strategies to reduce this risk.
Creating powerful antibody-based biological drugs which will form the basis of next generation therapeutics.
Develop prognostic tools and adjunctive therapies to predict and improve health outcomes for HIV patients.
Humans and pathogens exist in complex populations and environments, which impacts disease transmission and risk, prevention, treatment and public health responses.
Undertakes research to build the evidence base for policy and practice to improve outcomes for prisoners and ex-prisoners.
Understanding malaria dynamics in populations is key to implementing effective public health control measures.
Research focussed on immunity, vaccines, new treatments and clinical studies of malaria.
Malaria is a devastating parasitic disease that is becoming resistant to current medicines so new treatments need to be developed for future use.
Modelling plays a critical role in translating data into decision-making evidence.
Discovery of new drug targets for antiretroviral therapy and prevention.
This group manages HIV, Viral Hepatitis and STIs surveillance systems and conducts evaluations of projects and programs.
Supporting national tuberculosis programs in the Asia-Pacific region to address drug-resistant tuberculosis.
Accelerating towards elimination of vector-borne diseases such as malaria and lymphatic filariasis requires new approaches to diagnosis, surveillance and intervention.
Examining how HIV and hepatitis C virus attach to and enter cells.
Improving the understanding of hepatitis C and its transmission, and the management and care of people already infected with these viruses.
Examines the epidemiology and consequences of risk behaviours among young people.
To create and translate knowledge into better health, so no-one is left behind.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2023 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
